# The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients

> **NCT00002363** · PHASE1 · COMPLETED · sponsor: **Columbia Research Laboratories** · enrollment: 20 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Peptide Construction 3, Synthetic

## Key facts

- **NCT ID:** NCT00002363
- **Lead sponsor:** Columbia Research Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 20 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002363, "The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00002363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*